TWO COST-EFFECTIVENESS ANALYSES OF THE USE OF CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE VERSUS LENALIDOMIDE PLUS DEXAMETHASONE AND CARFILZOMIB PLUS DEXAMETHASONE VERSUS BORTEZOMIB PLUS DEXAMETHASONE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA IN COLOMBIA

被引：0
|
作者：
van Beurden-Tan, C. [1 ]
Forero, J. [2 ]
Coggia, A. [1 ]
Bustos Marquez, M. C. [2 ]
机构：
[1] Amgen Inc, Rotkreuz, Switzerland
[2] Amgen Inc, Bogota, Colombia
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN225
引用
收藏
页码：S480 / S480
页数：1
相关论文
共 50 条
  • [21] Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
    M A Dimopoulos
    A K Stewart
    T Masszi
    I Špička
    A Oriol
    R Hájek
    L Rosiñol
    D Siegel
    G G Mihaylov
    V Goranova-Marinova
    P Rajnics
    A Suvorov
    R Niesvizky
    A Jakubowiak
    J San-Miguel
    H Ludwig
    S Ro
    S Aggarwal
    P Moreau
    A Palumbo
    Blood Cancer Journal, 2017, 7 : e554 - e554
  • [22] KRD (CARFILZOMIB PLUS LENALIDOMIDE PLUS DEXAMETHASONE) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN CAMPANIA REGION: A ONE-YEAR SURVEY
    Palmieri, S.
    Rocco, S.
    Migliaccio, I.
    Cerchione, C.
    Catalano, L.
    Ferrara, K.
    Peluso, I.
    Monaco, G.
    Farina, G.
    Gagliardi, A.
    Barone, M.
    Esposito, D.
    Amico, V.
    Arcamone, M.
    Fontana, R.
    Sica, A.
    Pane, F.
    Ferrara, F.
    HAEMATOLOGICA, 2017, 102 : 126 - 126
  • [23] Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Wakabayashi, Masashi
    Tsukasaki, Kunihiro
    Miyamoto, Kenichi
    Maruyama, Dai
    Yamamoto, Kazuhito
    Takatsuka, Yoshifusa
    Kusumoto, Shigeru
    Kuroda, Junya
    Ando, Kiyoshi
    Kikukawa, Yoshitaka
    Masaki, Yasufumi
    Kobayashi, Miki
    Hanamura, Ichiro
    Asai, Hiroaki
    Nagai, Hirokazu
    Shimada, Kazuyuki
    Tsukamoto, Norifumi
    Inoue, Yoshiko
    Tobinai, Kensei
    CANCER SCIENCE, 2018, 109 (05) : 1552 - 1561
  • [24] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    BLOOD, 2019, 134 (05) : 421 - 431
  • [25] Isatuximab Plus Lenalidomide and Dexamethasone With Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma: The Benefit Study
    Leleu, Xavier
    Hulin, Cyrille
    Lambert, Jerome
    Bobin, Arthur
    Perrot, Aurore
    Manier, Salomon
    Jaccard, Arnaud
    Montes, Lydia
    Karlin, Lionel
    Godmer, Pascal
    Chalopin, Thomas
    Slama, Borhane
    Chretien, Marie Lorraine
    Laribi, Karim
    Dingremont, Claire
    Roul, Christophe
    Mariette, Clara
    Rigaudeau, Sophie
    Macro, Margaret
    Mohty, Mohamad
    Touzeau, Cyrille
    Moreau, Philippe
    Avet-Loiseau, Herve
    Corre, Jill
    Facon, Thierry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S33 - S33
  • [26] Lenalidomide plus dexamethasone in multiple myeloma
    Das, Manjulika
    LANCET ONCOLOGY, 2018, 19 (01) : E12 - E12
  • [27] Dexamethasone plus lenalidomide in treatment of multiple myeloma
    Deng Wei
    Journal of Medical Colleges of PLA, 2011, (01) : 29 - 33
  • [28] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10) : 701 - 710
  • [29] Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma
    Chari, Ajai
    Dimopoulos, Meletios-Athanasios
    Beksac, Meral
    Leleu, Xavier
    Weisel, Katja
    Richter, Joshua
    Dirnberger, Franziska
    Iskander, Karim
    Yusuf, Akeem
    Mikhael, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S142 - S142
  • [30] Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed multiple myeloma (IKEMA): final overall survival analysis
    Yong, Kwee
    Martin, Thomas
    Dimopoulos, Meletios
    Mikhael, Joseph
    Capra, Marcelo
    Facon, Thierry
    Hajek, Roman
    Spicka, Ivan
    Baker, Ross
    Kim, Kihyun
    Martinez, Gracia
    Min, Chang-Ki
    Pour, Ludek
    Leleu, Xavier
    Oriol, Albert
    Koh, Youngil
    Suzuki, Kenshi
    Casca, France
    Mace, Sandrine
    Risse, Marie-Laure
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S30 - S31
12345